"Utilization protein biochips in diagnostics ischemic damage infarction"@en . "4" . . "Tato pr\u00E1ce sleduje pacienty s akutn\u00EDm koron\u00E1rn\u00EDm syndromem a k diagnostice akutn\u00EDho infarktu myokardu (AIM) vyu\u017E\u00EDv\u00E1 zcela nov\u00E9 technologie proteinov\u00FDch bio\u010Dip\u016F. Snahou je nejenom ohodnotit tuto novou mo\u017Enost laboratorn\u00ED diagnostiky AIM, ale tak\u00E9 srovn\u00E1n\u00ED m\u00E9n\u011B zn\u00E1m\u00FDch kardiomarker\u016F se standardn\u00EDmi markery a posouzen\u00ED jejich vztahu ke klinick\u00FDm parametr\u016Fm. Materi\u00E1l a metody: Do studie bylo celkem za\u0159azeno 44 pacient\u016F s diagn\u00F3zou AIM a krevn\u00ED odb\u011Bry byly prov\u00E1d\u011Bny v den p\u0159ijet\u00ED, za 24 hodin a pot\u00E9 \u010Dtvrt\u00FD nebo p\u00E1t\u00FD den hospitalizace. Z kardiomarker\u016F byl testov\u00E1n panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP a GPBB) na bio\u010Dipov\u00E9m analyz\u00E1toru The Evidence Investigator TM od firmy Randox (Randox Laboratories Ltd., Velk\u00E1 Brit\u00E1nie). V\u00FDsledky: Na\u0161e pr\u00E1ce potvrdila t\u011Bsn\u00FD vztah FABP a GPBB k AIM a na z\u00E1klad\u011B jejich dynamiky je m\u016F\u017Eeme pova\u017Eovat za \u010Dasn\u00E9 kardiomarkery. Z\u00E1rove\u0148 jsme zjistili, \u017Ee FABP m\u00E1, stejn\u011B jako standardn\u00ED marker CKMB nebo TnI, tak\u00E9 prognostick\u00FD v\u00FDznam - vy\u0161\u0161\u00ED hodnoty jsou spojen\u00E9 se systolickou dysfunkc\u00ED. Tak\u00E9 jsme pouk\u00E1zali na mo\u017Enost vyu\u017Eit\u00ED bio\u010Dipov\u00E9ho analyz\u00E1toru p\u0159i diagnostice AIM, kdy za pom\u011Brn\u011B kr\u00E1tk\u00FD \u010Dasov\u00FD \u00FAsek z\u00EDsk\u00E1me v\u00FDsledky n\u011Bkolika analyt\u016F najednou, kter\u00E9 n\u00E1m tak podaj\u00ED \u0161ir\u0161\u00ED informace o prob\u00EDhaj\u00EDc\u00EDm AIM. Metoda proteinov\u00FDch bio\u010Dip\u016F p\u0159edstavuje v diagnostice AIM nov\u00FD efektivn\u00ED p\u0159\u00EDstup, kter\u00FD ale jist\u011B ke sv\u00E9mu roz\u0161\u00ED\u0159en\u00ED vy\u017Eaduje \u0159adu dal\u0161\u00EDch studi\u00ED. Z\u00E1v\u011Br: Metoda proteinov\u00FDch bio\u010Dip\u016F p\u0159edstavuje v diagnostice AIM nov\u00FD efektivn\u00ED p\u0159\u00EDstup, kter\u00FD ale jist\u011B ke sv\u00E9mu roz\u0161\u00ED\u0159en\u00ED vy\u017Eaduje \u0159adu dal\u0161\u00EDch studi\u00ED." . "Utilization protein biochips in diagnostics ischemic damage infarction"@en . "Pudil, Radek" . . "RIV/00216208:11150/14:10284259!RIV15-MSM-11150___" . . "Va\u0161atov\u00E1, Martina" . "I" . "Vyu\u017Eit\u00ED proteinov\u00FDch bio\u010Dip\u016F v diagnostice ischemick\u00E9ho po\u0161kozen\u00ED myokardu" . . "1210-7921" . "RIV/00216208:11150/14:10284259" . "Vyu\u017Eit\u00ED proteinov\u00FDch bio\u010Dip\u016F v diagnostice ischemick\u00E9ho po\u0161kozen\u00ED myokardu"@cs . "3"^^ . "11150" . "Objective: This study observes patients with acute coronary syndromes. To the diagnosis of acute myocardial infarction (AIM) we use the new proteins biochip technologies. The aim of this study is to evaluate the new strategy of laboratory diagnostic method and to confront the less known's cardio markers with the standard markers and with the clinical parameters. Material and methods: This study contains 44 patients with AIM and the blood samples were taken in the time of the admission, 24 hours later and then the fourth or fifth day of hospitalization. We tested the cardiac panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP and GPBB) on the biochip analyser The Evidence Investigator TM from Randox (Randox Laboratories Ltd., United Kingdom). Results: Our study confirms the close relationship between FABP and GPBB to AIM and we can consider these markers as early markers in the diagnosis of AIM. FABP has, as the standard markers CKMB or TnI, the prognostic value too (the higher values are associated with he systolic dysfunction). This study employs a new strategy of the biochip analyser in the diagnosis of AIM (in the same time we have the concentrations of more parameters and complex information about AIM). Conclusion: This method presents new interesting multianalytes approach to the diagnosis of the AIM. But this method requires a lot of further studies to verify this technology."@en . "22" . . . . . . . "Klinick\u00E1 biochemie a metabolismus" . . "[B64626BD0AD4]" . "4"^^ . "Tich\u00FD, Milo\u0161" . "http://www.cskb.cz/res/file/KBM-pdf/2014/2014-4/KBM-4-2014-Pudil-203.pdf" . . "Tato pr\u00E1ce sleduje pacienty s akutn\u00EDm koron\u00E1rn\u00EDm syndromem a k diagnostice akutn\u00EDho infarktu myokardu (AIM) vyu\u017E\u00EDv\u00E1 zcela nov\u00E9 technologie proteinov\u00FDch bio\u010Dip\u016F. Snahou je nejenom ohodnotit tuto novou mo\u017Enost laboratorn\u00ED diagnostiky AIM, ale tak\u00E9 srovn\u00E1n\u00ED m\u00E9n\u011B zn\u00E1m\u00FDch kardiomarker\u016F se standardn\u00EDmi markery a posouzen\u00ED jejich vztahu ke klinick\u00FDm parametr\u016Fm. Materi\u00E1l a metody: Do studie bylo celkem za\u0159azeno 44 pacient\u016F s diagn\u00F3zou AIM a krevn\u00ED odb\u011Bry byly prov\u00E1d\u011Bny v den p\u0159ijet\u00ED, za 24 hodin a pot\u00E9 \u010Dtvrt\u00FD nebo p\u00E1t\u00FD den hospitalizace. Z kardiomarker\u016F byl testov\u00E1n panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP a GPBB) na bio\u010Dipov\u00E9m analyz\u00E1toru The Evidence Investigator TM od firmy Randox (Randox Laboratories Ltd., Velk\u00E1 Brit\u00E1nie). V\u00FDsledky: Na\u0161e pr\u00E1ce potvrdila t\u011Bsn\u00FD vztah FABP a GPBB k AIM a na z\u00E1klad\u011B jejich dynamiky je m\u016F\u017Eeme pova\u017Eovat za \u010Dasn\u00E9 kardiomarkery. Z\u00E1rove\u0148 jsme zjistili, \u017Ee FABP m\u00E1, stejn\u011B jako standardn\u00ED marker CKMB nebo TnI, tak\u00E9 prognostick\u00FD v\u00FDznam - vy\u0161\u0161\u00ED hodnoty jsou spojen\u00E9 se systolickou dysfunkc\u00ED. Tak\u00E9 jsme pouk\u00E1zali na mo\u017Enost vyu\u017Eit\u00ED bio\u010Dipov\u00E9ho analyz\u00E1toru p\u0159i diagnostice AIM, kdy za pom\u011Brn\u011B kr\u00E1tk\u00FD \u010Dasov\u00FD \u00FAsek z\u00EDsk\u00E1me v\u00FDsledky n\u011Bkolika analyt\u016F najednou, kter\u00E9 n\u00E1m tak podaj\u00ED \u0161ir\u0161\u00ED informace o prob\u00EDhaj\u00EDc\u00EDm AIM. Metoda proteinov\u00FDch bio\u010Dip\u016F p\u0159edstavuje v diagnostice AIM nov\u00FD efektivn\u00ED p\u0159\u00EDstup, kter\u00FD ale jist\u011B ke sv\u00E9mu roz\u0161\u00ED\u0159en\u00ED vy\u017Eaduje \u0159adu dal\u0161\u00EDch studi\u00ED. Z\u00E1v\u011Br: Metoda proteinov\u00FDch bio\u010Dip\u016F p\u0159edstavuje v diagnostice AIM nov\u00FD efektivn\u00ED p\u0159\u00EDstup, kter\u00FD ale jist\u011B ke sv\u00E9mu roz\u0161\u00ED\u0159en\u00ED vy\u017Eaduje \u0159adu dal\u0161\u00EDch studi\u00ED."@cs . . . "systolic dysfunction; cardiac markers; protein biochip; acute myocardial infarction"@en . "Vyu\u017Eit\u00ED proteinov\u00FDch bio\u010Dip\u016F v diagnostice ischemick\u00E9ho po\u0161kozen\u00ED myokardu" . . "5"^^ . "55138" . "Vyu\u017Eit\u00ED proteinov\u00FDch bio\u010Dip\u016F v diagnostice ischemick\u00E9ho po\u0161kozen\u00ED myokardu"@cs . "Hor\u00E1kov\u00E1, Lucie" . . . "CZ - \u010Cesk\u00E1 republika" .